重复经颅磁刺激联合帕罗西汀治疗首发躯体形式障碍的效果观察

《重复经颅磁刺激联合帕罗西汀治疗首发躯体形式障碍的效果观察》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。

1、重复经颅磁刺激联合帕罗西汀治疗首发躯体形式障碍的效果观察党现炳刘萍王爱芹刘霞济宁市精神病防治院精神科摘要：口的：比较重复经颅磁刺激(rTMS)联合不同剂量帕罗西汀及单纯使用帕罗西汀对躯体形式障碍的疗效及安全性。方法:收治首发躯体形式障碍患者96例，随机分为观察一组、观察二组和对照组。分别给予rTMS联合10mg帕罗西汀、rTMS联合20mg帕罗西汀及单纯使用20mg帕罗西汀治疗，比较3组治疗效果。结果:观察一组和观察二组治疗后HAMD评分与HAME评分均低于对照组(P<0.05)。观察一组与观察二组总有效率显著高于对照组(P<0.05)。观察一组、观察二组与对照组的不良反应发生率分

2、别为15.64%、21.88%和43.75%,3组差异有统计学意义(IK0.05)。结论:rTMS联合小剂量(10mg)帕罗西汀治疗首发躯体形式障碍具有疗效好、起效快、安全性高的优势。关键词：重复经颅磁刺激;帕罗西汀;躯体形式障碍;基金:济宁市2015年科技计划107号课题。课题名称:重复经颅磁刺激(rTMS)合并小剂量帕罗西汀治疗躯体形式障碍的研究EffectofrepetitivetranscranialmagneticstimulationcombinedwithparoxetineinthetreatmentoffirstonsetsomatoformdisorderDan

3、gXianbingLiuPingWangAiqinLiuXiaPsychiatryDepartment,thePsychiatrieHospitalofJiningCity;Abstract：Objective:Tocomparetheefficacyandsafetyofrepetitivetranscranialmagneticstimulation(rTMS)combinedwithdifferentdosesofparoxetineandsingleuseofparoxetineinthetreatmentofsomatoformdisorders.Methods:96pa

4、tientswithfirstonsetsomcitoformdisorderwereselected.Theywererandomlydividedintotheobservationonegroup,theobservationtwogroupandthecontrolgroup.TheyweretreatedwithrTMScombinedwith10mgparoxetine,rTMScombinedwith20mgparoxetineandsingleuse20mgparoxetinerespectively.Wecomparedthetherapeuticeffectso

5、fthe3groups-Results:Aftertreatment,the11AMDscoreand11AMEscoreoftheobservationonegroupandtheobservationtwogroupwerelowerthanthecontrolgroup(P<0.05).Thetotaleffectiveratesoftheobservationonegroupandtheobservationtwogroupweresignificantlyhigherthanthecontrolgroup(P<0.05)•Theincideneeofadversereac

6、tionsoftheobservationonegroup,theobservationtwogroupandthecontrolgroupwas15.64%,21.88%and43.75%respectively,andthedifferencesamongthe3groupswerestatisticallysignificant(P<0.05).Conclusion:RTMScombinedwithsmalldose(10mg)paroxetineinthetreatmentoffirstonsetsomatoformdisorderhadobviousadvantages,

7、suchasgoodefficacy,quickonsctemdhighsafcty.Keyword：Repetitivetranscranialmagneticstimulation;Paroxetine;Sonidtofornidisorder;躯体形式障碍(SD)是一种以长期、持续性地相信或担心各种躯体症状的优势观念为主要特征的神经症，其躯体症状可涉及人体多系统，然而实验室或躯体检查多无相应的器质性疾病山。冃前临床主要采用选择性5-疑色胺(5-HT)再摄取抑制剂